Actinium Presents New ATNM-400 Data in KRAS and EGFR Mutant Models at SNMMI 2026 Supporting a Mutation-Agnostic Opportunity In Non-Small Cell Lung Cancer
Go back to Actinium Presents New ATNM-400 Data in KRAS and EGFR Mutant Models at SNMMI 2026 Supporting a Mutation-Agnostic Opportunity In Non-Small Cell Lung Cancer| Actinium Pharmaceuticals, Inc. (NYSE: ATNM) | Delayed: 1.05 +0.02 (1.94%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.03 | 52 Week High | $3.50 | |||
| Open | $1.02 | 52 Week Low | $0.86 | |||
| Day High | $1.05 | P/E | N/A | |||
| Day Low | $1.02 | EPS | $-7.61 | |||
| Volume | 62,140 | |||||
